Q32 Bio Inc. (QTTB): who owns it and who trades it
As of Nov 16, 2026, QTTB insiders reported 11 open-market sales worth $505K and 2 purchases worth $15M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jodie Pope Morrison (CEO), with $312K. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Q32 Bio
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns QTTB
70 funds and institutions reported QTTB shares worth $283M at the end of Q2 2026, about 74% of the company. The largest holder is Orbimed Advisors LLC with 13.8%.
Funds and institutions (13F) 74%Everyone else 26%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Orbimed Advisors LLC | 4.13M | 13.79% | $52.6M | +83% |
| Boxer Capital Management, LLC | 3.15M | 10.52% | $40.1M | New |
| Atlas Venture Life Science Advisors, LLC | 2.72M | 9.08% | $34.6M | +30% |
| Bvf Inc | 2.35M | 7.85% | $29.9M | New |
| Ra Capital Management, L.P. | 2.33M | 7.79% | $29.7M | New |
| Point72 Asset Management, L.P. | 1.17M | 3.92% | $14.9M | New |
| Opaleye Management Inc. | 931,000 | 3.11% | $11.9M | -26% |
| Logos Global Management LP | 800,000 | 2.67% | $10.2M | New |
| SummitTX Capital, L.P. | 733,774 | 2.45% | $9.3M | New |
| Vanguard Capital Management LLC | 518,803 | 1.73% | $6.6M | +69% |
| Ikarian Capital, LLC | 430,000 | 1.44% | $5.5M | New |
| Woodline Partners LP | 286,212 | 0.96% | $3.6M | New |
| American Century Companies Inc | 272,752 | 0.91% | $3.5M | +1353% |
| Sanofi | 244,083 | 0.82% | $3.1M | No change |
| Acadian Asset Management LLC | 218,234 | 0.73% | $2.8M | +26% |
| Acorn Capital Advisors, LLC | 216,171 | 0.72% | $2.8M | -31% |
| Renaissance Technologies LLC | 179,600 | 0.60% | $2.3M | -13% |
| Jane Street Group, LLC | 162,747 | 0.54% | $2.1M | +148% |
| Monimus Capital Management, LP | 132,036 | 0.44% | $1.7M | -2% |
| Boothbay Fund Management, LLC | 130,427 | 0.44% | $1.7M | New |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, QTTB insiders reported $15M of open-market purchases and $505K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | Lee Kalowski | CFO | Sale | 1,301 | $8.32 | $10.8K | Form 4 |
| Oct 6, 2026 | Jodie Pope Morrison | CEO | Sale | 3,221 | $8.32 | $26.8K | Form 4 |
| Oct 6, 2026 | Shelia M. Violette | Chief Scientific Officer | Sale | 917 | $8.32 | $7.6K | Form 4 |
| Aug 25, 2026 | Jodie Pope Morrison | CEO | Sale | 9,845 | $16.56 | $163K | Form 4 |
| Aug 25, 2026 | Lee Kalowski | CFO | Sale | 3,972 | $16.56 | $65.8K | Form 4 |
| Aug 25, 2026 | Shelia M. Violette | Chief Scientific Officer | Sale | 2,798 | $16.56 | $46.3K | Form 4 |
| May 28, 2026 | Diyong Xu | Director | Purchase | 1.25M | $8.00 | $10M | Form 4 |
| May 28, 2026 | Diyong Xu | Director | Purchase | 625,000 | $8.00 | $5M | Form 4 |
| Feb 25, 2026 | Lee Kalowski | CFO | Sale | 3,995 | $4.51 | $18K | Form 4 |
| Feb 25, 2026 | Jodie Pope Morrison | CEO | Sale | 9,896 | $4.51 | $44.6K | Form 4 |
| Feb 25, 2026 | Shelia M. Violette | Chief Scientific Officer | Sale | 2,815 | $4.51 | $12.7K | Form 4 |
| Dec 2, 2025 | Jodie Pope Morrison | CEO | Sale | 22,506 | $3.46 | $77.9K | Form 4 |
| Dec 2, 2025 | Lee Kalowski | CFO | Sale | 9,072 | $3.46 | $31.4K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Diyong Xu | Director, 10% owner | $15M | – | May 28, 2026 |
| Jodie Pope Morrison | CEO, Director | – | $312K | Oct 6, 2026 |
| Lee Kalowski | CFO and President | – | $126K | Oct 6, 2026 |
| Shelia M. Violette | Chief Scientific Officer | – | $66.7K | Oct 6, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
QTTB short interest
High short interest. 18.8% of QTTB shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 784%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 5.59M QTTB shares were sold short, 18.8% of the shares outstanding, down 1.1% from the report before. At the average daily volume of 460,730 shares, buying them all back would take about 12.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 5.59M | 18.78% | -1% | 460,730 | 12.1 |
| Oct 15, 2026 | 5.65M | 18.99% | +21% | 1.08M | 5.2 |
| Sep 30, 2026 | 4.67M | 15.69% | +24% | 1.08M | 4.3 |
| Sep 15, 2026 | 3.77M | 12.67% | +6% | 733,160 | 5.2 |
| Aug 31, 2026 | 3.56M | 11.95% | +13% | 372,926 | 9.5 |
| Aug 14, 2026 | 3.14M | 10.54% | +5% | 457,508 | 6.9 |
| Jul 31, 2026 | 3.00M | 20.51% | +33% | 794,972 | 3.8 |
| Jul 15, 2026 | 2.26M | 15.47% | +234% | 4.10M | 1.0 |
| Jun 30, 2026 | 677,047 | 4.63% | -25% | 421,449 | 1.6 |
| Jun 15, 2026 | 906,228 | 6.19% | +5% | 650,420 | 1.4 |
| May 29, 2026 | 861,749 | 5.89% | +36% | 2.75M | 1.0 |
| May 15, 2026 | 632,722 | 4.32% | -3% | 236,732 | 2.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Q32 Bio company events
Q32 Bio filed 16 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Sep 30, 2026AnnouncementThe Company announced additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe alopecia areata. Filing
- Sep 14, 2026AnnouncementThe Company announced the appointment of José Trevejo, M.D., Ph.D., as its Chief Medical Officer. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jul 15, 2026AgreementQ32 Bio Inc. entered into an underwriting agreement with Morgan Stanley & Co. LLC, Jefferies LLC, Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc., as representatives of the several underwriters named therein, pursuant to which the Company agreed to issue and sell an aggregate of (i) 6,027,399… Filing
- Jul 13, 2026AnnouncementQ32 Bio Inc. used a presentation in connection with its announcement of the topline results from the Part B of the SIGNAL-AA Phase 2a signal finding clinical trial evaluating bempikibart (ADX-914) in patients with alopecia areata, a copy of which is filed as Exhibit 99.1 to this Current Report on… Filing
- Jul 13, 2026AnnouncementThe Company announced topline results from the Part B of the SIGNAL-AA Phase 2a signal finding clinical trial evaluating bempikibart (ADX-914) in patients with alopecia areata. 36-Week Topline Results from Part B of the SIGNAL-AA Program The Part B portion of the SIGNAL-AA program is an open-label… Filing
- Jun 16, 2026VoteReported shareholder vote results. Filing
- May 27, 2026AgreementQ32 Bio Inc. entered into a securities purchase agreement with selected investors that qualify as “accredited investors”, as defined in Rule 501(a) of Regulation D promulgated under the United States Securities Act of 1933, as amended, to sell to the PIPE Investors an aggregate of (i) 6,725,000… Filing
- May 5, 2026ResultsReleased financial results. Filing
- Apr 24, 2026AnnouncementAs previously disclosed, on March 27, 2026, Q32 Bio Inc. entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co., with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of… Filing
- Mar 27, 2026AgreementQ32 Bio Inc. entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co., with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per… Filing
- Mar 10, 2026ResultsReleased financial results. Filing
- Feb 17, 2026AgreementQ32 Bio Inc. entered into a securities purchase agreement with certain institutional investors relating to the issuance and sale of (i) 1,666,679 shares of the Company’s common stock, par value $0.0001 per share, at a purchase price of $3.90 per share, and (ii) pre-funded warrants to purchase… Filing
- Dec 19, 2025LeadershipMark Iwicki had previously notified Q32 Bio Inc. of his intention to resign from the Company’s Board of Directors, effective as of December 31, 2025, to reduce the number of boards he serves on and to focus on his role as Chief Executive Officer of Inhibikase Therapeutics, Inc. Given the recently… Filing
- Dec 1, 2025DealThe information regarding the ADX-097 Asset Sale set forth in Item 1.01 above is hereby incorporated by reference into this Item 2.01. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Q32 Bio financials
Famous investors that hold QTTB
5 of the 50 well-known investors we track reported holding QTTB in their latest 13F filing. The largest position is Ken Griffin's, worth $5.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 623,395 | $5.2M | 0.0% | +417% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 345,402 | $2.9M | 0.0% | -71% |
| Israel Englander · Millennium Management | Q3 2026 | 248,006 | $2.1M | 0.0% | +2169% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 69,800 | $577K | 0.0% | -61% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 37,261 | $308K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 16 filings named QTTB in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | T. Rowe Price Associates, Inc. | 13G | 5.0% |
| Nov 16, 2026 | T. Rowe Price Associates, Inc. | 13G | 5.0% |
| Nov 16, 2026 | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 6.3% |
| Nov 16, 2026 | Sirenia Capital Management LP | 13G/A | 4.2% |
| Nov 16, 2026 | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 6.3% |
| Nov 16, 2026 | RA Capital Management, L.P. | 13G/A | 9.9% |
| Nov 16, 2026 | RA Capital Management, L.P. | 13G/A | 9.9% |
| Nov 16, 2026 | Sirenia Capital Management LP | 13G/A | 4.2% |
| Nov 6, 2026 | Boxer Capital Management, LLC | 13G/A | 7.9% |
| Nov 6, 2026 | Opaleye Management Inc. | 13G/A | 3.8% |
| Nov 6, 2026 | Boxer Capital Management, LLC | 13G/A | 7.9% |
| Nov 6, 2026 | Opaleye Management Inc. | 13G/A | 3.8% |
| Oct 28, 2026 | BANK OF AMERICA CORP /DE/ | 13G | 7.4% |
| Oct 28, 2026 | BANK OF AMERICA CORP /DE/ | 13G | 7.4% |
| Oct 9, 2026 | Frazier Life Sciences Public Fund, L.P. | 13G | 5.9% |
| Oct 9, 2026 | Frazier Life Sciences Public Fund, L.P. | 13G | 5.9% |
Questions about Q32 Bio Inc. (QTTB) stock
Who owns the most QTTB stock?
The largest reported owner of Q32 Bio Inc. (QTTB) is Orbimed Advisors LLC, with 13.8% of the company. In total, 70 funds and institutions reported holding QTTB at the end of Q2 2026, together about 74% of the shares. See the largest owners.
Are QTTB insiders buying or selling?
In the last 12 months, QTTB insiders reported 2 open-market purchases worth $15M and 11 sales worth $505K. The latest trade was on Oct 6, 2026. See every trade.
What is the short interest in QTTB?
As of Oct 30, 2026, 5.59M QTTB shares were sold short, 18.8% of the shares outstanding, down 1.1% from the report before. At the average daily volume of 460,730 shares, buying them all back would take about 12.1 trading days (days to cover). See the history.
Which famous investors hold QTTB?
5 of the 50 well-known investors we track reported QTTB in their latest 13F filing, including Ken Griffin, Steve Cohen, Israel Englander. The largest position is worth $5.2M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.